Hideshima, T
Cottini, F
Ohguchi, H
Jakubikova, J
Gorgun, G
Mimura, N
Tai, Y-T
Munshi, N C
Richardson, P G
Anderson, K C
Article History
Received: 1 April 2015
Accepted: 14 April 2015
First Online: 15 May 2015
Competing interests
: TH is a consultant for Acetylon Pharmaceuticals. KCA is a member of advisory board for Celgene, Millennium, Gilead, Bristol-Myers Squibb and Sanofi-Aventis, and is a scientific founder and member of advisory board of Acetylon and Oncopep. Y-TT is a consultant for Onyx. PGR is a member of advisory board for Celgene, Millennium, Johnson & Johnson, Novartis and Bristol-Myers Squibb. NCM is a member of advisory board for Millennium, Celgene, and Novartis. The remaining authors declare no conflicts of interests.